- Price as of: Jan 29, 10:24 PM EST
- Drug manufacturers - major
NVS Stock Dividend DataAdd NVS to Watchlist
NVS Daily Snapshot
- Quote Time:
- Jan 29, 10:24 PM
- Today's Volume:
- Open Price:
- Day's Range:
- $97.93 - $99.21
- Previous Close:
- 52 Week Low / High:
- $77.90 - $102.59
- Percent Off 52 Week High:
NVS Dividend Growth History
Last 5 Yrs
Last 3 Yrs
|Reveal More Dividend Growth History for NVS||5.5%||13.7%||No Payout Increase Last Year|
NVS Dividend History
|Payout Amount||Declared Date||Ex-Dividend Date||Record Date||Pay Date ▼||Qualified Dividend?||Payout Type||Frequency|
NVS Company Profile
Novartis AG (NVS) is a healthcare solutions provider that offers medicines, preventive vaccines and diagnostic tools, generic pharmaceuticals, and consumer health products around the globe. It operates in four segments: pharmaceuticals, vaccines and diagnostics, sandoz, and consumer health. Novartis was founded in 1895 and is headquartered in Basel, Switzerland.
January 27, 2015
Before the opening bell on Tuesday, a number of big name, dividend paying companies announced their quarterly earnings. Below, we look at these earnings reports and break down the important points for investors.
Jul 31, 2014Here at Dividend.com, we constantly emphasize the importance of strong fundamentals when it comes to making any investment decision. However, with...
May 29, 2014If you're struggling to find attractive investment opportunities at home without taking on handfuls of risk, you're not alone. Many investors have...
Wednesday's Analyst Moves: Apple Inc., Hillshire Brands Co, Intel Corporation, More (AAPL, HSH, INTC, More)May 28, 2014Before Wednesday’s opening bell, a number of big name dividend stocks were the subject of analyst moves. Below, we highlight the important analyst...
Today's Pre-Market Earnings: Caterpillar Inc., Eli Lilly and Co, Time Warner Cable Inc, More (CAT, LLY, TWC, More)Apr 24, 2014Before Thursday's opening bell, a number of big name, dividend paying companies announced their quarterly earnings. Below, we look at these...
Novartis AG (ADR) Sells Diagnostics Business for $1.68B (NVS)Nov 11, 2013On Monday, healthcare company Novartis AG (ADR) (NVS) announced that it has sold its diagnostics business for $1.68 billion in cash. NVS's Strategic Review As part of the company's strategic review, NVS has sold its blood transfusion diagnostics business to Barcelona-based Grifols. The business was previously a part of Chiron, a biotechnology company that was acquired by NVS in 2006. NVS's chief executive Joseph Jimenez reported that the sale was part of a company plan to focus on its larger businesses. The company's diagnostics business also works with Johnson & Johnson (JNJ) and with Hologic (HOLX). The deal has been approved by both of these companies. Additional Sales May be in NVS's Future NVS's decision to sell off the business was highly expected by analysts. The company may also decide to divest in its vaccines and diagnostics, over-the-counter (OTC) products, and animal health businesses. Several other pharmaceutical companies have been restructuring their businesses to meet investor demands. Stock Performance Novartis shares were mostly flat during pre-market trading Monday. The stock is up 22% YTD.Expand to read the full story
Jun 6, 2013Jefferies reported on Thursday that healthcare company, Novartis AG (NVS) is now the top pick for European pharmaceuticals. The firm, which...
Supreme Court Of India Rejects Patent Protection for Novartis' Glivec (NVS)Apr 2, 2013Healthcare solution provider, Novartis AG (NVS) failed to win patent protection for Glivec on Monday. The court in India has rejected patent protection for NVS's cancer drug Glivec. The denial of the patent protection came as a major disappointment to the company, but as a victory for makers of low priced generic drugs. India's generic drug industry has turned into a $13 billion a year industry, which comes to a great relief to a majority of the country's 1.2 billion residents who are unable to afford expensive patent protected drugs. India's Cipla Ltd and Natco Pharma Ltd are two companies that will benefit from the rejection of patent protection. The companies already sell a generic version of the drug at a price one-tenth of the patented drug. The decision to block the patent protection for NVS comes after a legal battle which began in 2006. There has been much controversy regarding high priced drugs in the country. Novartis shares were up 59 cents, or 0.83% during premarket trading Tuesday. The stock has increased 28% in the past year. The Bottom Line Shares of Novartis AG (NVS) have a 3.56% yield, based on Monday's closing price of $71.06. Novartis AG (NVS) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
JPMorgan Upgrades Novartis to "Overweight" (NVS)Mar 15, 2013JPMorgan reported on Friday that it has upgraded healthcare product giant, Novartis AG (NVS) . The firm has increased its rating for the company from "Neutral" to "Overweight." An analyst from the firm commented, "we upgrade Novartis to overweight from Neutral with a new 18 month price target of Sfr 78 assuming the stock can approach a sector multiple by mid 2014 which reflects FCF growth beyond 2019 of just below 1%." Novartis shares were up 56 cents, or 0.81% during Friday morning trading. The stock has increased 28% in the past year. The Bottom Line Shares of Novartis AG (NVS) have a 3.64% yield, based on Friday morning's price of $69.57. Novartis AG (NVS) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
Novartis Reports Higher Profits; Chairman Steps Down (NVS)Jan 23, 2013Healthcare solution provider, Novartis(NVS) reported a surge in earnings for the fourth quarter on Wednesday, beating analysts estimates. The Basel, Switzerland based company saw a 42% increase in fourth quarter profit, reporting earnings of $2.08 billion, or 84 cents per share, from $1.21 billion, or 49 cents per share last year. Excluding special items, earnings for the quarter came in at $3.10 billion, or $1.27 per share, beating analysts estimate of $1.19 per share. Revenue remained flat at $14.83 billion, from $14.78 billion last year. Sales during 2013 are expected to drop due to an expired patent on the company's hypertension drug Diovan. FY2012 profit increased by 4% to $9.62 billion from $9.25 billion last year. Additionally, the company announced that chief executive and chairman, Daniel Vasella will be leaving the board in February at the annual shareholders meeting. The board suggests that chairman of Bayer HealthCare, Joerg Reinhardt replace Vasella. Vasella has been with the company for a total of 25 years, spending 14 years as CEO, and 14 years as chairman. Novartis shares were up $2.72, or 4.18% during premarket trading Wednesday. The stock has increased 18% in the past year. The Bottom Line Shares of Novartis (NVS) have a 3.78% dividend yield, based on last night's closing stock price of $65.13. The stock has technical support in the $60-$62 price area. The shares are trading at all-time highs. Novartis(NVS) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story